PNN New Delhi [India] January 8 Thangam Cancer Center Namakkal is organizing a three days conference on peritoneal surface ...

Sacituzumab tirumotecan is under clinical development by Merck and currently in Phase II for Peritoneal Cancer.

IMPACT Therapeutics ('IMPACT'), a biopharmaceutical company focusing on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality, is pleased to announce that ...

INCB-123667 is under clinical development by Incyte and currently in Phase I for Peritoneal Cancer. According to GlobalData, Phase I drugs for Peritoneal Cancer have an 85% phase transition success ...

A nurse, foster mom and the primary provider for a family of eight, Shelly Sepulveda has devoted her life to taking care of ...

Adding hyperthermic intraperitoneal chemotherapy to surgery did not improve progression-free survival in platinum-sensitive recurrent ovarian cancer.

Many cancers upregulate an amino acid transporter to fuel their growth, making this protein a promising tool in tumor ...

Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical ...

A woman diagnosed with stage four cancer has shared the hidden symptoms that were initially dismissed by doctors.

Research suggests a new drug slowed the growth of prostate cancer cells, including those with a resistance to the hormone ...

The drug, known as NXP800, works by targeting the heat shock factor 1 (HSF1) pathway, a cellular protective mechanism that is ...

The drug, known as NXP800, works by targeting the heat shock factor 1 (HSF1) pathway, a cellular protective mechanism that is ...